K. M. Steve Lo

2.5k total citations
7 papers, 303 citations indexed

About

K. M. Steve Lo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, K. M. Steve Lo has authored 7 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Pathology and Forensic Medicine. Recurrent topics in K. M. Steve Lo's work include Advanced Breast Cancer Therapies (2 papers), Phytoestrogen effects and research (1 paper) and CNS Lymphoma Diagnosis and Treatment (1 paper). K. M. Steve Lo is often cited by papers focused on Advanced Breast Cancer Therapies (2 papers), Phytoestrogen effects and research (1 paper) and CNS Lymphoma Diagnosis and Treatment (1 paper). K. M. Steve Lo collaborates with scholars based in United States and Italy. K. M. Steve Lo's co-authors include Alfred I. Neugut, David W. Kinne, Elizabeth L. Kaufman, Andrea B. Troxel, Judith S. Jacobson, Linda T. Vahdat, Victor R. Grann, Anne A. Moore, Harold J. Burstein and Gwen Nichols and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Surgical Oncology and Bone Marrow Transplantation.

In The Last Decade

K. M. Steve Lo

4 papers receiving 269 citations

Peers

Countries citing papers authored by K. M. Steve Lo

Since Specialization

Citations

This map shows the geographic impact of K. M. Steve Lo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. M. Steve Lo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. M. Steve Lo more than expected).

Fields of papers citing papers by K. M. Steve Lo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. M. Steve Lo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. M. Steve Lo. The network helps show where K. M. Steve Lo may publish in the future.

Co-authorship network of co-authors of K. M. Steve Lo

This figure shows the co-authorship network connecting the top 25 collaborators of K. M. Steve Lo. A scholar is included among the top collaborators of K. M. Steve Lo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. M. Steve Lo. K. M. Steve Lo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial 2025 ·Annals of Surgical Oncology ·Anna Weiss, Qingchun Jin, Nabihah Tayob, Eileen Wrabel, Michelle K. DeMeo, (unknown), Michael Constantine, Meredith Faggen, Caroline Block, Mary Anne Fenton, K. M. Steve Lo, Thomas H. Openshaw, Denise A. Yardley, Laura C. Kennedy, Isabelle Bedrosian, Elizabeth A. Mittendorf, Rinath Jeselsohn, Otto Metzger, Tari A. King	0
2	The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer. 2025 ·Journal of Clinical Oncology ·Erica L. Mayer, Dario Trapani, Se Eun Kim, Meredith Faggen, Natalie Sinclair, Pedro Sanz-Altamira, Chiara Battelli, (unknown), K. M. Steve Lo, (unknown), (unknown), (unknown), Leticia Varella, Sarah Sammons, Susan Schumer, Philip D. Poorvu, Erin R. Wallace, (unknown), Nabihah Tayob, Sara M. Tolaney	0
3	Cell-free circulating chromatin profiling for epigenomic characterization of mechanisms of response and resistance to sacituzumab govitecan in breast cancer. 2025 ·Journal of Clinical Oncology ·Ana C. Garrido-Castro, Aparna Gorthi, Se Eun Kim, Anthony D’Ippolito, Rita Nanda, Yara Abdou, Amy S. Clark, (unknown), (unknown), Natalie Sinclair, K. M. Steve Lo, (unknown), Nancy U. Lin, Harold J. Burstein, Elizabeth A. Mittendorf, Corrie Painter, Matthew L. Eaton, J. Carl Barrett, Nabihah Tayob, Sara M. Tolaney	0
4	SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. 2024 ·Journal of Clinical Oncology ·Ana C. Garrido-Castro, Se Eun Kim, (unknown), Rita Nanda, Lisa A. Carey, Amy S. Clark, (unknown), (unknown), Natalie Sinclair, K. M. Steve Lo, Amy Thomas, Eileen Wrabel, Tess A. O’Meara, Nancy U. Lin, Harold J. Burstein, (unknown), David L. Rimm, Elizabeth A. Mittendorf, Nabihah Tayob, Sara M. Tolaney	20
5	Tandem thiotepa with autologous hematopoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies 2017 ·Pediatric Blood & Cancer ·Diana S. Osorio, Ira J. Dunkel, (unknown), Rakesh K. Goyal, K. M. Steve Lo, Jonathan L. Finlay, Sharon L. Gardner	6
6	Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma 2005 ·Bone Marrow Transplantation ·Kyriakos P. Papadopoulos, (unknown), Lauren Allison Wiebe, (unknown), James H. Garvin, Gwen Nichols, (unknown), K. M. Steve Lo, Donna Skerrett, David Bernstein, Elizabeth Sharpe, David G. Savage	6
7	Randomized Trial of Black Cohosh for the Treatment of Hot Flashes Among Women With a History of Breast Cancer 2001 ·Journal of Clinical Oncology ·Judith S. Jacobson, Andrea B. Troxel, (unknown), (unknown), Linda T. Vahdat, David W. Kinne, K. M. Steve Lo, Anne A. Moore, (unknown), Elizabeth L. Kaufman, Alfred I. Neugut, Victor R. Grann	271

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact